{21 (futibatinib 4 MG Oral Tablet) } Pack

RxCUI: 2628203
RxNorm name: {21 (futibatinib 4 MG Oral Tablet) } Pack
Display name: {21 (futibatinib 4 MG Oral Tablet) } Pack
Full name: {21 (futibatinib 4 MG Oral Tablet) } Pack
Term type: GPCK
Status: DailyMed mapping
Updated: 2026-06-04 23:38:46

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
LYTGOBI	FUTIBATINIB	TAIHO PHARMACEUTICAL CO., LTD.	0b1332a1-0581-4707-9bf6-1eccfa39bef4	2025-10-27	Warnings, Adverse reactions	Exact identifier rxcui: 2628203

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
0b1332a1-0581-4707-9bf6-1eccfa39bef4	{21 (futibatinib 4 MG Oral Tablet) } Pack [GPCK] · futibatinib 12 MG Daily Dose Pack, 4 MG (21) [PSN] · futibatinib 12 MG Daily Dose Pack, 4 MG (21) [SY]	3	8	These highlights do not include all the information needed to use LYTGOBI safely and effectively. See full prescribing information for LYTGOBI. LYTGOBI ® (futibatinib) tablets, for oral use Initial U.S. Approval: 2022	20251027